The potent and selective adenosine A2AR antagonists P400 and P625 protect against symptoms in autoimmune experimental encephalomyelitis by attenuating neuroinflammation and demyelination

Key Points

• Adenosine A2AR antagonists P400 and P625 significantly reduce neuroinflammation, improving symptoms.
• Experimental autoimmune encephalomyelitis shows diminished demyelination with treatment from P400 and P625.
• Assessment using antagonists in a preclinical model indicates a direct protective effect on the nervous system.
• These findings support further exploration of P400 and P625 as potential therapies for autoimmune conditions.